Home

Features

  • The CDMO/CMO Report: Cell and Gene TherapiesByPatricia Van Arnum

    The CDMO/CMO Report: Cell and Gene Therapies
    By

    Although a niche market, cell and gene therapy development and manufacturing continues to be an active area of investment by CDMOs/CMOs. Facing limited industry capacity, both pure-play CDMOs and bio/pharma companies with CDMO services continue to expand. A roundup of the latest expansions.


  • Pharma Innovation: AI in Drug ManufacturingByPatricia Van Arnum

    Pharma Innovation: AI in Drug Manufacturing
    By

    What is the potential of artificial intelligence (AI) in pharmaceutical manufacturing and what regulatory considerations come into play, including between CDMOs/CMOs and sponsor companies? The FDA has issued a discussion paper to highlight key issues and is seeking input from the industry.


DCAT MEMBER COMPANY COMMUNITY